Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $45.40 in the last session, up 0.93% from day before closing price of $44.98. In other words, the price has increased by $0.93 from its previous closing price. On the day, 1.81 million shares were traded. RNA stock price reached its highest trading level at $45.63 during the session, while it also had its lowest trading level at $44.2.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.
Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 06 ’24 when Boyce Sarah sold 28,000 shares for $43.35 per share. The transaction valued at 1,213,822 led to the insider holds 205,043 shares of the business.
LEVIN ARTHUR A sold 5,000 shares of RNA for $225,069 on Jul 19 ’24. The Director now owns 14,830 shares after completing the transaction at $45.01 per share. On Jul 09 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 28,000 shares for $39.93 each. As a result, the insider received 1,118,082 and left with 205,043 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5317293568 and an Enterprise Value of 3694319360. For the stock, the TTM Price-to-Sale (P/S) ratio is 470.28 while its Price-to-Book (P/B) ratio in mrq is 4.06. Its current Enterprise Value per Revenue stands at 348.554 whereas that against EBITDA is -13.069.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.80, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 9.82%, while the 200-Day Moving Average is calculated to be 99.60%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.61M shares per day over the past 3-months and 1452200 shares per day over the past 10 days. A total of 109.80M shares are outstanding, with a floating share count of 100.15M. Insiders hold about 8.79% of the company’s shares, while institutions hold 99.92% stake in the company. Shares short for RNA as of 1722384000 were 12952998 with a Short Ratio of 8.03, compared to 1719532800 on 10834579. Therefore, it implies a Short% of Shares Outstanding of 12952998 and a Short% of Float of 14.850000999999999.
